TRIL took a lot of hits for on target tox. TTI621 is the only anti CD47 that works mono/combo, AML complete molecular remission, TTI-621/rituximab combination obtained robust lymphoma regressions.
Has 90002 shown a PR in 2 years?? "low dose tox pretty high. How will an even safer low dose reach tissue from non-blood cancers? Maybe $CELG #CD47 drug is the answer?"
$TRIL low dose tox pretty high. How will an even safer low dose reach tissue from non-blood cancers? Maybe $CELG#CD47 drug is the answer?